HR Execs on the Move

Swan Hospice

www.swanhospice.com

 
Swan Hospice is a healthcare provider that offers personalized end-of-life care plans for terminally ill adult patients and support for their families.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

TestZone

TestZone is a global health security provider of multi-layered screening programs to keep spaces safer. Founded by internationally recognized experts in medical diagnostics and public health, we create customizable, on-site solutions for any institution or business that needs to keep its doors open by keeping its people healthy amid always evolving health threats.

Kaberline Healthcare

Kaberline Healthcare is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shippert Medical

Shippert Medical is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. (LeMaitre Vascular) is a provider of medical devices and implants for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices.